ES2672099T3

ES2672099T3 - Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal

Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal Download PDF

Info

Publication number: ES2672099T3
Authority: ES; Spain
Prior art keywords: methyl; compound; eye; fluoro; alkyl
Prior art date: 2011-07-04
Legal status : Active

Application number

ES12741268.2T

Other languages

English (en)

Spanish (es)

Inventor

Giulio FERRARI

Current Assignee

IRBM Science Park SpA

Original Assignee

IRBM Science Park SpA

Priority date

2011-07-04

Filing date

2012-07-04

Publication date

2018-06-12

2012-07-04 Application filed by IRBM Science Park SpA filed Critical IRBM Science Park SpA

2018-06-12 Application granted granted Critical

2018-06-12 Publication of ES2672099T3 publication Critical patent/ES2672099T3/es

Status Active legal-status Critical Current

2032-07-04 Anticipated expiration legal-status Critical

Links

206010055665 Corneal neovascularisation Diseases 0.000 title claims abstract description 80
201000000159 corneal neovascularization Diseases 0.000 title claims abstract description 80
238000011282 treatment Methods 0.000 title claims abstract description 48
108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims abstract description 12
102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims abstract description 9
239000002464 receptor antagonist Substances 0.000 title claims abstract description 9
229940044551 receptor antagonist Drugs 0.000 title claims abstract description 9
-1 bafetupitant Chemical compound 0.000 claims abstract description 139
150000001875 compounds Chemical class 0.000 claims abstract description 79
210000004087 cornea Anatomy 0.000 claims abstract description 40
BARDROPHSZEBKC-OITMNORJSA-N fosaprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NC(=O)N(P(O)(O)=O)N1 BARDROPHSZEBKC-OITMNORJSA-N 0.000 claims abstract description 24
229960002891 fosaprepitant Drugs 0.000 claims abstract description 23
CVXJAPZTZWLRBP-MUUNZHRXSA-N n-[(2r)-1-[acetyl-[(2-methoxyphenyl)methyl]amino]-3-(1h-indol-3-yl)propan-2-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)acetamide Chemical compound COC1=CC=CC=C1CN(C(C)=O)C[C@H](NC(=O)CN1CCC(CC1)N1CCCCC1)CC1=CNC2=CC=CC=C12 CVXJAPZTZWLRBP-MUUNZHRXSA-N 0.000 claims abstract description 22
229950005286 lanepitant Drugs 0.000 claims abstract description 21
150000003839 salts Chemical class 0.000 claims abstract description 19
230000002265 prevention Effects 0.000 claims abstract description 17
ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims abstract description 10
229960001372 aprepitant Drugs 0.000 claims abstract description 9
239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims description 40
239000005557 antagonist Substances 0.000 claims description 29
102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 24
101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 24
239000003513 alkali Substances 0.000 claims description 22
239000013543 active substance Substances 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 18
206010015911 Eye burns Diseases 0.000 claims description 17
239000000017 hydrogel Substances 0.000 claims description 15
206010023332 keratitis Diseases 0.000 claims description 12
230000009467 reduction Effects 0.000 claims description 12
208000015181 infectious disease Diseases 0.000 claims description 10
206010061218 Inflammation Diseases 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
230000004054 inflammatory process Effects 0.000 claims description 8
239000003242 anti bacterial agent Substances 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
230000006872 improvement Effects 0.000 claims description 5
238000001356 surgical procedure Methods 0.000 claims description 5
230000000472 traumatic effect Effects 0.000 claims description 5
230000002458 infectious effect Effects 0.000 claims description 4
208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
241000589516 Pseudomonas Species 0.000 claims description 3
201000002154 Pterygium Diseases 0.000 claims description 3
208000008303 aniridia Diseases 0.000 claims description 3
230000003412 degenerative effect Effects 0.000 claims description 3
208000024908 graft versus host disease Diseases 0.000 claims description 3
230000002035 prolonged effect Effects 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
206010061041 Chlamydial infection Diseases 0.000 claims description 2
208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
206010013774 Dry eye Diseases 0.000 claims description 2
208000005100 Herpetic Keratitis Diseases 0.000 claims description 2
206010072138 Limbal stem cell deficiency Diseases 0.000 claims description 2
206010073938 Ophthalmic herpes simplex Diseases 0.000 claims description 2
206010034277 Pemphigoid Diseases 0.000 claims description 2
241000191940 Staphylococcus Species 0.000 claims description 2
241000194017 Streptococcus Species 0.000 claims description 2
239000003443 antiviral agent Substances 0.000 claims description 2
230000008901 benefit Effects 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
230000000813 microbial effect Effects 0.000 claims description 2
238000004321 preservation Methods 0.000 claims description 2
230000000750 progressive effect Effects 0.000 claims description 2
208000009043 Chemical Burns Diseases 0.000 claims 2
208000035143 Bacterial infection Diseases 0.000 claims 1
206010008422 Chemical burns of eye Diseases 0.000 claims 1
208000032544 Cicatrix Diseases 0.000 claims 1
208000032536 Pseudomonas Infections Diseases 0.000 claims 1
208000036142 Viral infection Diseases 0.000 claims 1
230000016571 aggressive behavior Effects 0.000 claims 1
230000001363 autoimmune Effects 0.000 claims 1
208000022362 bacterial infectious disease Diseases 0.000 claims 1
230000004968 inflammatory condition Effects 0.000 claims 1
231100000241 scar Toxicity 0.000 claims 1
230000037387 scars Effects 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
230000009385 viral infection Effects 0.000 claims 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 93
239000001257 hydrogen Substances 0.000 description 61
229910052739 hydrogen Inorganic materials 0.000 description 61
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 55
239000000203 mixture Substances 0.000 description 52
210000001508 eye Anatomy 0.000 description 47
229910052736 halogen Inorganic materials 0.000 description 38
150000002367 halogens Chemical class 0.000 description 38
150000002431 hydrogen Chemical class 0.000 description 31
239000002253 acid Substances 0.000 description 28
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 27
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 26
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
125000004093 cyano group Chemical group *C#N 0.000 description 26
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 26
125000004435 hydrogen atom Chemical group [H]* 0.000 description 25
241000699670 Mus sp. Species 0.000 description 24
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 23
230000000699 topical effect Effects 0.000 description 23
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 23
DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 21
206010029113 Neovascularisation Diseases 0.000 description 21
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 20
229920000642 polymer Polymers 0.000 description 20
125000000217 alkyl group Chemical group 0.000 description 17
229910052757 nitrogen Inorganic materials 0.000 description 17
239000008188 pellet Substances 0.000 description 17
102100024304 Protachykinin-1 Human genes 0.000 description 16
238000000034 method Methods 0.000 description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
230000002829 reductive effect Effects 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 15
101800003906 Substance P Proteins 0.000 description 15
230000033115 angiogenesis Effects 0.000 description 15
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 14
239000003814 drug Substances 0.000 description 13
239000000654 additive Substances 0.000 description 12
239000008194 pharmaceutical composition Substances 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
239000000872 buffer Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 10
230000000694 effects Effects 0.000 description 10
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
229920002674 hyaluronan Polymers 0.000 description 9
229960003160 hyaluronic acid Drugs 0.000 description 9
238000002513 implantation Methods 0.000 description 9
239000007788 liquid Substances 0.000 description 9
229910052760 oxygen Inorganic materials 0.000 description 9
239000001301 oxygen Substances 0.000 description 9
229940068196 placebo Drugs 0.000 description 9
239000000902 placebo Substances 0.000 description 9
ZHIAARPZLAPMHX-ZCFIWIBFSA-N (1r)-1-[3,5-bis(trifluoromethyl)phenyl]-n-methylethanamine Chemical compound CN[C@H](C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZHIAARPZLAPMHX-ZCFIWIBFSA-N 0.000 description 8
229930105110 Cyclosporin A Natural products 0.000 description 8
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
108010036949 Cyclosporine Proteins 0.000 description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
125000005842 heteroatom Chemical group 0.000 description 8
230000002757 inflammatory effect Effects 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
208000037816 tissue injury Diseases 0.000 description 8
230000002792 vascular Effects 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 7
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
125000003545 alkoxy group Chemical group 0.000 description 7
210000004204 blood vessel Anatomy 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 7
239000000243 solution Substances 0.000 description 7
229910052717 sulfur Inorganic materials 0.000 description 7
239000011593 sulfur Chemical group 0.000 description 7
125000003944 tolyl group Chemical group 0.000 description 7
238000011200 topical administration Methods 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
235000010443 alginic acid Nutrition 0.000 description 6
229920000615 alginic acid Polymers 0.000 description 6
229960001265 ciclosporin Drugs 0.000 description 6
230000006378 damage Effects 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
125000005843 halogen group Chemical group 0.000 description 6
238000011532 immunohistochemical staining Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
125000004433 nitrogen atom Chemical group N* 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
QJNMFINEIFVNMK-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]ethanamine Chemical compound NCCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QJNMFINEIFVNMK-UHFFFAOYSA-N 0.000 description 5
125000006163 5-membered heteroaryl group Chemical group 0.000 description 5
125000006164 6-membered heteroaryl group Chemical group 0.000 description 5
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
102000009410 Chemokine receptor Human genes 0.000 description 5
108050000299 Chemokine receptor Proteins 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
239000003018 immunosuppressive agent Substances 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
150000003254 radicals Chemical group 0.000 description 5
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
ZGNPLCMMVKCTHM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-morpholin-4-ylpyridin-3-yl]propanamide Chemical compound C=1N=C(N2CCOCC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZGNPLCMMVKCTHM-UHFFFAOYSA-N 0.000 description 4
SOYGYIIYPHINQZ-UHFFFAOYSA-N CC(C=C(C=C1)F)=C1N(CCNC1)C1C(O)=O.CNCC1=CC(Cl)=CC(Cl)=C1 Chemical compound CC(C=C(C=C1)F)=C1N(CCNC1)C1C(O)=O.CNCC1=CC(Cl)=CC(Cl)=C1 SOYGYIIYPHINQZ-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
239000004098 Tetracycline Substances 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000000556 agonist Substances 0.000 description 4
229940072056 alginate Drugs 0.000 description 4
238000003556 assay Methods 0.000 description 4
229950006529 befetupitant Drugs 0.000 description 4
229960000397 bevacizumab Drugs 0.000 description 4
229910052799 carbon Chemical group 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
210000000744 eyelid Anatomy 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
230000012010 growth Effects 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
229960002180 tetracycline Drugs 0.000 description 4
229930101283 tetracycline Natural products 0.000 description 4
235000019364 tetracycline Nutrition 0.000 description 4
150000003522 tetracyclines Chemical class 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
229960000281 trometamol Drugs 0.000 description 4
XWNBGDJPEXZSQM-VZOBGQTKSA-N (2r,4s)-4-[(8as)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamide Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2C[C@H]3N(C(CC3)=O)CC2)=CC=C(F)C=C1C XWNBGDJPEXZSQM-VZOBGQTKSA-N 0.000 description 3
LISLXJGPJUAEHU-UHFFFAOYSA-N 3-[3,5-bis(trifluoromethyl)phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LISLXJGPJUAEHU-UHFFFAOYSA-N 0.000 description 3
125000003341 7 membered heterocyclic group Chemical group 0.000 description 3
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 3
206010011039 Corneal perforation Diseases 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 3
102100037346 Substance-P receptor Human genes 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
230000004453 corneal transparency Effects 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
239000000178 monomer Substances 0.000 description 3
CUBGFICHXDHDKU-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCN(C)CC1 CUBGFICHXDHDKU-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
230000007170 pathology Effects 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229920001983 poloxamer Polymers 0.000 description 3
150000004804 polysaccharides Chemical class 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 3
229940080818 propionamide Drugs 0.000 description 3
229960003876 ranibizumab Drugs 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
CCIWVEMVBWEMCY-RCFOMQFPSA-N (2s)-1-[(3as,4s,7as)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one Chemical compound COC1=CC=CC=C1[C@H](C)C(=O)N1C[C@H](C(CC[C@@]2(O)C=3C(=CC=CC=3)OC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[C@H]2C1 CCIWVEMVBWEMCY-RCFOMQFPSA-N 0.000 description 2
SBBYBXSFWOLDDG-JLTOFOAXSA-N (2s)-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperazine-1-carboxamide Chemical compound C1([C@H]2CNCCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=CC=C(F)C=C1C SBBYBXSFWOLDDG-JLTOFOAXSA-N 0.000 description 2
XPNMCDYOYIKVGB-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C(C)C)C=C1CN[C@@H]1[C@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 XPNMCDYOYIKVGB-CONSDPRKSA-N 0.000 description 2
XILNRORTJVDYRH-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N2C(=NN=N2)C(F)(F)F)=CC=CC=C1 XILNRORTJVDYRH-HKUYNNGSSA-N 0.000 description 2
125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 2
MVXKCCDGIKNDQF-UHFFFAOYSA-N 1-[(3,5-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]imidazol-2-one Chemical compound C1CN(C)CCC1(N1C(N(CC=2C=C(Cl)C=C(Cl)C=2)C=C1)=O)C1=CC=C(F)C=C1 MVXKCCDGIKNDQF-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
125000001963 4 membered heterocyclic group Chemical group 0.000 description 2
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 2
125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
108091023037 Aptamer Proteins 0.000 description 2
101100043727 Caenorhabditis elegans syx-2 gene Proteins 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
101100535673 Drosophila melanogaster Syn gene Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010040722 Neurokinin-2 Receptors Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
241000589517 Pseudomonas aeruginosa Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
102100037342 Substance-K receptor Human genes 0.000 description 2
102000003141 Tachykinin Human genes 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
206010064996 Ulcerative keratitis Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
108091008605 VEGF receptors Proteins 0.000 description 2
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
230000002411 adverse Effects 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
208000002205 allergic conjunctivitis Diseases 0.000 description 2
230000004075 alteration Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
210000003484 anatomy Anatomy 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
208000024998 atopic conjunctivitis Diseases 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
239000002981 blocking agent Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229960002626 clarithromycin Drugs 0.000 description 2
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
239000003885 eye ointment Substances 0.000 description 2
125000001207 fluorophenyl group Chemical group 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
WGPRORNLEWIBMY-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C=C(F)C=CC=1C(C1(F)CCNCC1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 WGPRORNLEWIBMY-UHFFFAOYSA-N 0.000 description 2
OLOCSAMKFGITFZ-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(F)C=CC=2)CCN(C)CC1 OLOCSAMKFGITFZ-UHFFFAOYSA-N 0.000 description 2
OXGUVKBVGBHGCD-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(C)C(F)=CC=2)CCN(C)CC1 OXGUVKBVGBHGCD-UHFFFAOYSA-N 0.000 description 2
KIVIARGCODRSTP-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-2-[4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCNCC1 KIVIARGCODRSTP-UHFFFAOYSA-N 0.000 description 2
KQRTULUMOKTQES-UHFFFAOYSA-N n-[1-(3,5-dichlorophenyl)ethyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCN(C)CC1 KQRTULUMOKTQES-UHFFFAOYSA-N 0.000 description 2
ZGHMSACBXSLVOL-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCN(C)CC1 ZGHMSACBXSLVOL-UHFFFAOYSA-N 0.000 description 2
KXHRKAVQKDLHBQ-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCNCC1 KXHRKAVQKDLHBQ-UHFFFAOYSA-N 0.000 description 2
IXQYVBPAOAKSJA-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-3-(3-fluoropiperidin-3-yl)-n-methylpropanamide Chemical compound C=1C=C(F)C=CC=1C(C1(F)CNCCC1)CC(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IXQYVBPAOAKSJA-UHFFFAOYSA-N 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
229940069265 ophthalmic ointment Drugs 0.000 description 2
229960003407 pegaptanib Drugs 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
108060008037 tachykinin Proteins 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
229960000707 tobramycin Drugs 0.000 description 2
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
IPOAQLGRQPKMAR-FYZOBXCZSA-N (1r)-1-[3,5-bis(trifluoromethyl)phenyl]-n-methylethanamine;hydrochloride Chemical compound Cl.CN[C@H](C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IPOAQLGRQPKMAR-FYZOBXCZSA-N 0.000 description 1
DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
JXTVFSQNFDCOHZ-GOEBONIOSA-N (2r,4s)-2-(4-fluoro-2-methylphenyl)-4-(4-methyl-2-oxopiperazin-1-yl)piperidine-1-carboxylic acid Chemical compound O=C1CN(C)CCN1[C@@H]1C[C@H](C=2C(=CC(F)=CC=2)C)N(C(O)=O)CC1 JXTVFSQNFDCOHZ-GOEBONIOSA-N 0.000 description 1
JYUBSEKBLPTPRS-LADGPHEKSA-N (2r,4s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-n-methyl-4-piperazin-1-ylpiperidine-1-carboxamide Chemical compound N1([C@H](C[C@H](CC1)N1CCNCC1)C=1C(=CC(F)=CC=1)C)C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JYUBSEKBLPTPRS-LADGPHEKSA-N 0.000 description 1
OMPCVMLFFSQFIX-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-[(5-tert-butyl-2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CN[C@@H]1[C@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 OMPCVMLFFSQFIX-CONSDPRKSA-N 0.000 description 1
PGVSXRHFXJOMGW-YBZGWEFGSA-N (2s,3s)-2-benzhydryl-n-[(5-tert-butyl-2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;2-hydroxypropane-1,2,3-tricarboxylic acid;hydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O.COC1=CC=C(C(C)(C)C)C=C1CN[C@@H]1[C@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 PGVSXRHFXJOMGW-YBZGWEFGSA-N 0.000 description 1
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
WAVDSLLYAQBITE-UHFFFAOYSA-N (4-ethenylphenyl)methanamine Chemical compound NCC1=CC=C(C=C)C=C1 WAVDSLLYAQBITE-UHFFFAOYSA-N 0.000 description 1
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
LDXQLWNPGRANTO-GOSISDBHSA-N (9r)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C([C@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C1=O)C)CN(C(C2=NC=CC=C22)=O)C1=C2C1=CC=C(C)C=C1 LDXQLWNPGRANTO-GOSISDBHSA-N 0.000 description 1
125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
OXRSCXFOUBLJAR-ODZAUARKSA-N (z)-but-2-enedioic acid;methanamine Chemical compound NC.OC(=O)\C=C/C(O)=O OXRSCXFOUBLJAR-ODZAUARKSA-N 0.000 description 1
XRRDFIPYLFCYLU-UHFFFAOYSA-N 1,3,5-trimethylbenzene Chemical group [CH2]C1=CC(C)=CC(C)=C1 XRRDFIPYLFCYLU-UHFFFAOYSA-N 0.000 description 1
YIBVKKCIOSMWON-UHFFFAOYSA-N 1-(4-fluoro-2-methylphenyl)piperazine-2-carboxylic acid Chemical compound CC1=CC(F)=CC=C1N1C(C(O)=O)CNCC1 YIBVKKCIOSMWON-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
RTXKXJFSIVJIAU-UHFFFAOYSA-N 1-[(3,5-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]imidazolidin-2-one Chemical compound C1CN(C)CCC1(C=1C=CC(F)=CC=1)N1C(=O)N(CC=2C=C(Cl)C=C(Cl)C=2)CC1 RTXKXJFSIVJIAU-UHFFFAOYSA-N 0.000 description 1
GNDKFMAPXGTFHT-UHFFFAOYSA-N 1-[(3,5-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)piperidin-4-yl]imidazol-2-one Chemical compound C1=CC(F)=CC=C1C1(N2C(N(CC=3C=C(Cl)C=C(Cl)C=3)C=C2)=O)CCNCC1 GNDKFMAPXGTFHT-UHFFFAOYSA-N 0.000 description 1
HBIMJZQDNNVFNR-UHFFFAOYSA-N 1-[(3-chloronaphthalen-1-yl)methyl]-3-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]imidazol-2-one Chemical compound C1CN(C)CCC1(N1C(N(CC=2C3=CC=CC=C3C=C(Cl)C=2)C=C1)=O)C1=CC=C(F)C=C1 HBIMJZQDNNVFNR-UHFFFAOYSA-N 0.000 description 1
RPDFDSQFBCJTDY-GAQXSTBRSA-N 1-[(3s)-3-(3,4-dichlorophenyl)-3-[2-(4-phenyl-1-azoniabicyclo[2.2.2]octan-1-yl)ethyl]piperidin-1-yl]-2-(3-propan-2-yloxyphenyl)ethanone Chemical compound CC(C)OC1=CC=CC(CC(=O)N2C[C@](CC[N+]34CCC(CC3)(CC4)C=3C=CC=CC=3)(CCC2)C=2C=C(Cl)C(Cl)=CC=2)=C1 RPDFDSQFBCJTDY-GAQXSTBRSA-N 0.000 description 1
VOIMVJZOPHONLU-UHFFFAOYSA-N 1-[1-(3,5-dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]imidazol-2-one Chemical compound C1=CN(C2(CCN(C)CC2)C=2C=CC(F)=CC=2)C(=O)N1C(C)C1=CC(Cl)=CC(Cl)=C1 VOIMVJZOPHONLU-UHFFFAOYSA-N 0.000 description 1
VUINBJBLYHLCFK-UHFFFAOYSA-N 1-[1-(3-chloronaphthalen-1-yl)ethyl]-3-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]imidazol-2-one Chemical compound C=1C(Cl)=CC2=CC=CC=C2C=1C(C)N(C1=O)C=CN1C1(C=2C=CC(F)=CC=2)CCN(C)CC1 VUINBJBLYHLCFK-UHFFFAOYSA-N 0.000 description 1
ADTNSTHKMIPKIJ-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ADTNSTHKMIPKIJ-UHFFFAOYSA-N 0.000 description 1
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
NXBDLTJZZIKTKL-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C NXBDLTJZZIKTKL-UHFFFAOYSA-N 0.000 description 1
HVYQZCLEPABLCN-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;methyl 2-methylprop-2-enoate;prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C HVYQZCLEPABLCN-UHFFFAOYSA-N 0.000 description 1
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NCPKXVSLLSEPDP-UHFFFAOYSA-N 2-(4-acetylpiperazin-1-yl)-6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methylphenyl)-8,9-dihydro-7h-pyrimido[4,5-b][1,5]oxazocin-5-one Chemical compound C1CN(C(=O)C)CCN1C(N=C1C=2C(=CC=CC=2)C)=NC2=C1C(=O)N(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)CCCO2 NCPKXVSLLSEPDP-UHFFFAOYSA-N 0.000 description 1
OYWUUEUHGOENKD-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)piperidin-4-yl]-n-[(3,5-dibromophenyl)methyl]-n-methylacetamide Chemical compound C1CN(CC2CC2)CCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 OYWUUEUHGOENKD-UHFFFAOYSA-N 0.000 description 1
ZLNYUCXXSDDIFU-LJAQVGFWSA-N 2-[1-[2-[(2r)-4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]piperidin-4-yl]-2-methylpropanamide Chemical compound C1CC(C(C)(C)C(N)=O)CCN1CC[C@]1(C=2C=C(Cl)C(Cl)=CC=2)OCCN(C(=O)CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 ZLNYUCXXSDDIFU-LJAQVGFWSA-N 0.000 description 1
ILOQXAWUMHGLQS-UHFFFAOYSA-N 2-[4-(1-benzofuran-5-yl)-1-methylpiperidin-4-yl]-n-[1-(3-chloronaphthalen-1-yl)ethyl]-n-methylacetamide Chemical compound C=1C(Cl)=CC2=CC=CC=C2C=1C(C)N(C)C(=O)CC1(C=2C=C3C=COC3=CC=2)CCN(C)CC1 ILOQXAWUMHGLQS-UHFFFAOYSA-N 0.000 description 1
PUMQASALSAPJEO-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)-1-methylpiperidin-4-yl]-n-[1-(3,5-dibromophenyl)ethyl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(Cl)C=CC=2)CCN(C)CC1 PUMQASALSAPJEO-UHFFFAOYSA-N 0.000 description 1
QSEXPEXXHIAOFV-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)-1-methylpiperidin-4-yl]-n-[1-(3,5-dichlorophenyl)ethyl]-n-methylacetamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(Cl)C=CC=2)CCN(C)CC1 QSEXPEXXHIAOFV-UHFFFAOYSA-N 0.000 description 1
OEEFNSQUTAISGV-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)piperidin-4-yl]-n-[(3,5-dibromophenyl)methyl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C=C(Cl)C=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 OEEFNSQUTAISGV-UHFFFAOYSA-N 0.000 description 1
CBCZFQUWFWZMNV-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)piperidin-4-yl]-n-[1-(3,5-dibromophenyl)ethyl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(Cl)C=CC=2)CCNCC1 CBCZFQUWFWZMNV-UHFFFAOYSA-N 0.000 description 1
PYDSTENQHKZPJA-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)piperidin-4-yl]-n-[1-(3,5-dichlorophenyl)ethyl]-n-methylacetamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(Cl)C=CC=2)CCNCC1 PYDSTENQHKZPJA-UHFFFAOYSA-N 0.000 description 1
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
MHQBYWLEDIMOBI-UHFFFAOYSA-N 3-(3,5-dibromophenyl)-2-[4-(4-fluorophenyl)-1-methylazepan-4-yl]-N-methylpropanamide Chemical compound BrC=1C=C(C=C(C1)Br)CC(C(=O)NC)C1(CCN(CCC1)C)C1=CC=C(C=C1)F MHQBYWLEDIMOBI-UHFFFAOYSA-N 0.000 description 1
ICXZQVDUXUITNI-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-[(3,5-dibromophenyl)methyl]-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C1(F)CCNCC1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 ICXZQVDUXUITNI-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
FUBZPDNXSJJNQQ-UHFFFAOYSA-N 4-[[3-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-2-oxoimidazolidin-1-yl]methyl]naphthalene-2-carbonitrile Chemical compound C1CN(C)CCC1(C=1C=CC(F)=CC=1)N1C(=O)N(CC=2C3=CC=CC=C3C=C(C=2)C#N)CC1 FUBZPDNXSJJNQQ-UHFFFAOYSA-N 0.000 description 1
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
OBYVLIBOYUNTFR-UHFFFAOYSA-N 6-fluoro-4-[[3-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-2-oxoimidazolidin-1-yl]methyl]naphthalene-2-carbonitrile Chemical compound C1CN(C)CCC1(C=1C=CC(F)=CC=1)N1C(=O)N(CC=2C3=CC(F)=CC=C3C=C(C=2)C#N)CC1 OBYVLIBOYUNTFR-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
JTKRUJSSJQQJOF-UHFFFAOYSA-N CC(C=C(C=C1)F)=C1N(CCNC1)C1C(O)=O.CNCC(C=C1)=CC(Br)=C1Br Chemical compound CC(C=C(C=C1)F)=C1N(CCNC1)C1C(O)=O.CNCC(C=C1)=CC(Br)=C1Br JTKRUJSSJQQJOF-UHFFFAOYSA-N 0.000 description 1
FNAUMCRAWQYEAG-KUGOCAJQSA-N CC(N(CC1)CCN1[C@@H](CC1)C[C@H](C(C=C2)=C(C)C=C2F)N1C(O)=O)=O.CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound CC(N(CC1)CCN1[C@@H](CC1)C[C@H](C(C=C2)=C(C)C=C2F)N1C(O)=O)=O.CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FNAUMCRAWQYEAG-KUGOCAJQSA-N 0.000 description 1
UMFHMBUMKIWPNR-UTONKHPSSA-N CC1=C([C@@H](CCNCC2)N2C(O)=O)C=CC(F)=C1.CNCC1=CC(Cl)=CC(Cl)=C1 Chemical compound CC1=C([C@@H](CCNCC2)N2C(O)=O)C=CC(F)=C1.CNCC1=CC(Cl)=CC(Cl)=C1 UMFHMBUMKIWPNR-UTONKHPSSA-N 0.000 description 1
HPYUFOYBOZQPIN-UTONKHPSSA-N CC1=C([C@@H](CNCCC2)N2C(O)=O)C=CC(F)=C1.CNCC1=CC(Cl)=CC(Cl)=C1 Chemical compound CC1=C([C@@H](CNCCC2)N2C(O)=O)C=CC(F)=C1.CNCC1=CC(Cl)=CC(Cl)=C1 HPYUFOYBOZQPIN-UTONKHPSSA-N 0.000 description 1
LLUQOSJXFSKCFH-UHFFFAOYSA-N CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1.O=C(CC1)N2C1CNCC2 Chemical compound CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1.O=C(CC1)N2C1CNCC2 LLUQOSJXFSKCFH-UHFFFAOYSA-N 0.000 description 1
229940123672 Cadherin antagonist Drugs 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
108010078777 Colistin Proteins 0.000 description 1
206010055114 Colon cancer metastatic Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
208000028006 Corneal injury Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000014260 Fungal keratitis Diseases 0.000 description 1
241000223218 Fusarium Species 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
101100134925 Gallus gallus COR6 gene Chemical group 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
101000600912 Homo sapiens Substance-K receptor Proteins 0.000 description 1
101000655188 Homo sapiens Tachykinin-3 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical compound O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
229940123038 Integrin antagonist Drugs 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
JSHDAORXSNJOBA-UHFFFAOYSA-N Isopropyl hexanoate Chemical compound CCCCCC(=O)OC(C)C JSHDAORXSNJOBA-UHFFFAOYSA-N 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
206010023335 Keratitis interstitial Diseases 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000014692 Lyell syndrome Diseases 0.000 description 1
TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical class CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
229940127387 Neurokinin 1 Antagonists Drugs 0.000 description 1
108010040716 Neurokinin-3 Receptors Proteins 0.000 description 1
102000002003 Neurokinin-3 Receptors Human genes 0.000 description 1
102100029409 Neuromedin-K receptor Human genes 0.000 description 1
101800000923 Neuropeptide K Proteins 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000243985 Onchocerca volvulus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000004100 Oxytetracycline Substances 0.000 description 1
101150044441 PECAM1 gene Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920003072 Plasdone™ povidone Polymers 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108091008103 RNA aptamers Proteins 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
101000916225 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Cullin-4 Proteins 0.000 description 1
208000032183 Scleromalacia Diseases 0.000 description 1
229940123578 Selectin antagonist Drugs 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000007124 Tachykinin Receptors Human genes 0.000 description 1
108010072901 Tachykinin Receptors Proteins 0.000 description 1
102100033009 Tachykinin-3 Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108010053950 Teicoplanin Proteins 0.000 description 1
208000018656 Terrien marginal degeneration Diseases 0.000 description 1
229920002807 Thiomer Polymers 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940114077 acrylic acid Drugs 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229960001232 anecortave Drugs 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000000964 angiostatic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
239000000607 artificial tear Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
229960004099 azithromycin Drugs 0.000 description 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
229960003623 azlocillin Drugs 0.000 description 1
JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
229960003669 carbenicillin Drugs 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
XGGTZCKQRWXCHW-WMTVXVAQSA-N casopitant Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2CCN(CC2)C(C)=O)=CC=C(F)C=C1C XGGTZCKQRWXCHW-WMTVXVAQSA-N 0.000 description 1
229960003778 casopitant Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
201000005533 central corneal ulcer Diseases 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
229960005233 cineole Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229940047766 co-trimoxazole Drugs 0.000 description 1
229960003346 colistin Drugs 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
208000021921 corneal disease Diseases 0.000 description 1
210000003683 corneal stroma Anatomy 0.000 description 1
201000007717 corneal ulcer Diseases 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
239000000430 cytokine receptor antagonist Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229950007605 dapitant Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960002398 demeclocycline Drugs 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
229960001585 dicloxacillin Drugs 0.000 description 1
QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical group [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229940108890 emend Drugs 0.000 description 1
210000000871 endothelium corneal Anatomy 0.000 description 1
210000000105 enteric nervous system Anatomy 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
208000011323 eye infectious disease Diseases 0.000 description 1
229950000331 ezlopitant Drugs 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002073 fluorescence micrograph Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
VRQHBYGYXDWZDL-OOZCZQCLSA-N fosaprepitant dimeglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NN(P(O)(O)=O)C(=O)N1 VRQHBYGYXDWZDL-OOZCZQCLSA-N 0.000 description 1
229940044880 fosaprepitant dimeglumine Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229920000578 graft copolymer Polymers 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940048921 humira Drugs 0.000 description 1
229940014041 hyaluronate Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
230000004941 influx Effects 0.000 description 1
201000006904 interstitial keratitis Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000005304 joining Methods 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000005772 leucine Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
235000013490 limbo Nutrition 0.000 description 1
239000000865 liniment Substances 0.000 description 1
229940040145 liniment Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229940076783 lucentis Drugs 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229940092110 macugen Drugs 0.000 description 1
229960003640 mafenide Drugs 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960002505 maropitant Drugs 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229960000198 mezlocillin Drugs 0.000 description 1
YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
229960004023 minocycline Drugs 0.000 description 1
239000003595 mist Substances 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
PKTTXXWZAUSUTH-RBFZIWAESA-N n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluorophenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound CN([C@H](C)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C(=O)CC(C1(F)CCNCC1)C1=CC=C(F)C=C1 PKTTXXWZAUSUTH-RBFZIWAESA-N 0.000 description 1
NXLUTEDAEFXMQR-BJKOFHAPSA-N n-[(2r,4s)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2[C@@H](C[C@H](CC2)NC(=O)C=2C3=CC=CC=C3N=CC=2)CC=2C=CC(Cl)=CC=2)=C1 NXLUTEDAEFXMQR-BJKOFHAPSA-N 0.000 description 1
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
SKXVHKHMWJBQCP-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[1-[2-(dimethylamino)-2-oxoethyl]-4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CN(CC(=O)N(C)C)CCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 SKXVHKHMWJBQCP-UHFFFAOYSA-N 0.000 description 1
KBGITZDEJWREGG-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[1-ethyl-4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CN(CC)CCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 KBGITZDEJWREGG-UHFFFAOYSA-N 0.000 description 1
FTLVICBKHBUZKS-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C=C(F)C(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 FTLVICBKHBUZKS-UHFFFAOYSA-N 0.000 description 1
LABGAISISHWSFW-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C=C(F)C(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 LABGAISISHWSFW-UHFFFAOYSA-N 0.000 description 1
YOQJLRIIOAJDKZ-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(3,4-dimethylphenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C=C(C)C(C)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 YOQJLRIIOAJDKZ-UHFFFAOYSA-N 0.000 description 1
TWCRITRSWQJWKA-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C=C(F)C=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 TWCRITRSWQJWKA-UHFFFAOYSA-N 0.000 description 1
UMAXDBLPJXAGBO-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(3-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C=C(F)C=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 UMAXDBLPJXAGBO-UHFFFAOYSA-N 0.000 description 1
LAZGFGUCJYBTJM-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C(=CC(F)=CC=1)C)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 LAZGFGUCJYBTJM-UHFFFAOYSA-N 0.000 description 1
OHBATSBWDOWIHA-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C(=CC(F)=CC=1)C)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 OHBATSBWDOWIHA-UHFFFAOYSA-N 0.000 description 1
KLBWSLPBLMGIMR-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C=C(C)C(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 KLBWSLPBLMGIMR-UHFFFAOYSA-N 0.000 description 1
APVVVQYIXSHNFF-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C=C(C)C(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 APVVVQYIXSHNFF-UHFFFAOYSA-N 0.000 description 1
SBIHQWGCVPZYOK-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 SBIHQWGCVPZYOK-UHFFFAOYSA-N 0.000 description 1
JMGILTGHFIRXNO-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluorophenyl)azepan-4-yl]-n-methylacetamide Chemical compound C1CCNCCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 JMGILTGHFIRXNO-UHFFFAOYSA-N 0.000 description 1
IEGOVDNNVDRMGV-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-2-[4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 IEGOVDNNVDRMGV-UHFFFAOYSA-N 0.000 description 1
WEZZDMMPMIPMPI-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-3-(3,4-dichlorophenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C1(F)CCNCC1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 WEZZDMMPMIPMPI-UHFFFAOYSA-N 0.000 description 1
CBMGTEFUFDPTRE-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C=C(F)C=C(C)C=1C(C1(F)CCNCC1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 CBMGTEFUFDPTRE-UHFFFAOYSA-N 0.000 description 1
CLKKHXPWZNLYTD-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-n-methyl-2-(1-methyl-4-phenylpiperidin-4-yl)acetamide Chemical compound C1CN(C)CCC1(C=1C=CC=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 CLKKHXPWZNLYTD-UHFFFAOYSA-N 0.000 description 1
APJWCTJEVJXCJW-UHFFFAOYSA-N n-[(3,5-dibromophenyl)methyl]-n-methyl-2-(4-phenylpiperidin-4-yl)acetamide Chemical compound C1CNCCC1(C=1C=CC=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(Br)=C1 APJWCTJEVJXCJW-UHFFFAOYSA-N 0.000 description 1
QCFKFTAAYXDMST-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-2-[3-fluoro-4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCC(F)C1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Cl)=CC(Cl)=C1 QCFKFTAAYXDMST-UHFFFAOYSA-N 0.000 description 1
UGPFLVWKAQRSJW-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-(2-methoxyethyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CN(CCOC)CCC1(C=1C(=CC(F)=CC=1)C)CC(=O)N(C)CC1=CC(Cl)=CC(Cl)=C1 UGPFLVWKAQRSJW-UHFFFAOYSA-N 0.000 description 1
PCIYLGYWJDFXTM-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C(=CC(F)=CC=1)C)CC(=O)N(C)CC1=CC(Cl)=CC(Cl)=C1 PCIYLGYWJDFXTM-UHFFFAOYSA-N 0.000 description 1
UKVZBBOFTAACDW-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C(=CC(F)=CC=1)C)CC(=O)N(C)CC1=CC(Cl)=CC(Cl)=C1 UKVZBBOFTAACDW-UHFFFAOYSA-N 0.000 description 1
WHAURRGDIYUJKM-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Cl)=CC(Cl)=C1 WHAURRGDIYUJKM-UHFFFAOYSA-N 0.000 description 1
VYJWMIJCAOBBJQ-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-3-(4-fluorophenyl)-n-methyl-3-piperidin-4-ylpropanamide Chemical compound C1CNCCC1C(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Cl)=CC(Cl)=C1 VYJWMIJCAOBBJQ-UHFFFAOYSA-N 0.000 description 1
XFEFBFOPLLPADO-UHFFFAOYSA-N n-[(3-bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(C#N)=C1 XFEFBFOPLLPADO-UHFFFAOYSA-N 0.000 description 1
ZQMQUKLVAUQUEA-UHFFFAOYSA-N n-[(3-bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C1CNCCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(Br)=CC(C#N)=C1 ZQMQUKLVAUQUEA-UHFFFAOYSA-N 0.000 description 1
JKMBTCHEQYHODT-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(F)C(F)=CC=2)CCN(C)CC1 JKMBTCHEQYHODT-UHFFFAOYSA-N 0.000 description 1
GURNMMQXHJFSIY-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(F)C=CC=2)CCNCC1 GURNMMQXHJFSIY-UHFFFAOYSA-N 0.000 description 1
LPGKLBRZOSQCQG-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=C(C)C(F)=CC=2)CCNCC1 LPGKLBRZOSQCQG-UHFFFAOYSA-N 0.000 description 1
XGIULTTWQOPCSJ-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-n-methyl-2-(1-methyl-4-phenylpiperidin-4-yl)acetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC=CC=2)CCN(C)CC1 XGIULTTWQOPCSJ-UHFFFAOYSA-N 0.000 description 1
IBFWKPCDEAEHPF-UHFFFAOYSA-N n-[1-(3,5-dibromophenyl)ethyl]-n-methyl-2-(4-phenylpiperidin-4-yl)acetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC=CC=2)CCNCC1 IBFWKPCDEAEHPF-UHFFFAOYSA-N 0.000 description 1
GDQICJDTYOYKRA-UHFFFAOYSA-N n-[1-(3,5-dichlorophenyl)ethyl]-2-[4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCNCC1 GDQICJDTYOYKRA-UHFFFAOYSA-N 0.000 description 1
VYKODOLVEHTYCH-UHFFFAOYSA-N n-[1-(3,5-dichlorophenyl)ethyl]-3-(4-fluorophenyl)-3-[1-(2-methoxyethyl)piperidin-4-yl]-n-methylpropanamide Chemical compound C1CN(CCOC)CCC1C(C=1C=CC(F)=CC=1)CC(=O)N(C)C(C)C1=CC(Cl)=CC(Cl)=C1 VYKODOLVEHTYCH-UHFFFAOYSA-N 0.000 description 1
JXQJQRCVLZWBOJ-UHFFFAOYSA-N n-[1-(3,5-dichlorophenyl)ethyl]-3-(4-fluorophenyl)-n-methyl-3-piperidin-4-ylpropanamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1C(C)N(C)C(=O)CC(C=1C=CC(F)=CC=1)C1CCNCC1 JXQJQRCVLZWBOJ-UHFFFAOYSA-N 0.000 description 1
NAWPHODMHWLJKY-UHFFFAOYSA-N n-[1-(3-chloronaphthalen-1-yl)ethyl]-2-(1,2-dimethyl-4-phenylpiperidin-4-yl)-n-methylacetamide Chemical compound C=1C(Cl)=CC2=CC=CC=C2C=1C(C)N(C)C(=O)CC1(C=2C=CC=CC=2)CCN(C)C(C)C1 NAWPHODMHWLJKY-UHFFFAOYSA-N 0.000 description 1
DRXBWLBZWAJIEF-UHFFFAOYSA-N n-[1-(3-chloronaphthalen-1-yl)ethyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Cl)=CC2=CC=CC=C2C=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCN(C)CC1 DRXBWLBZWAJIEF-UHFFFAOYSA-N 0.000 description 1
ZZEDIURUGGTDOH-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-(4-fluoro-2-methylphenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC1(C=2C(=CC(F)=CC=2)C)CCNCC1 ZZEDIURUGGTDOH-UHFFFAOYSA-N 0.000 description 1
LEILNUMLEXGOOI-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-(4-fluorophenyl)azepan-4-yl]-n-methylacetamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCCNCC1 LEILNUMLEXGOOI-UHFFFAOYSA-N 0.000 description 1
IHDDHUUAVBFFBQ-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(2,4-dichlorophenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC(C1(F)CCNCC1)C1=CC=C(Cl)C=C1Cl IHDDHUUAVBFFBQ-UHFFFAOYSA-N 0.000 description 1
MVWMLUABWPHDSI-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC(C1(F)CCNCC1)C1=CC=C(F)C=C1C MVWMLUABWPHDSI-UHFFFAOYSA-N 0.000 description 1
PKTTXXWZAUSUTH-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluorophenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC(C1(F)CCNCC1)C1=CC=C(F)C=C1 PKTTXXWZAUSUTH-UHFFFAOYSA-N 0.000 description 1
PPKADJAJJQNDAR-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-n-methyl-2-(1-methyl-4-phenylpiperidin-4-yl)acetamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC=CC=2)CCN(C)CC1 PPKADJAJJQNDAR-UHFFFAOYSA-N 0.000 description 1
VZHSEYRKQIMGOP-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-n-methyl-2-(4-phenylpiperidin-4-yl)acetamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)N(C)C(=O)CC1(C=2C=CC=CC=2)CCNCC1 VZHSEYRKQIMGOP-UHFFFAOYSA-N 0.000 description 1
SUFHNAMRRNNRQH-UHFFFAOYSA-N n-[2-(3,5-dibromophenyl)propan-2-yl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCN(C)CC1 SUFHNAMRRNNRQH-UHFFFAOYSA-N 0.000 description 1
ZNYREVKCPQKHSI-UHFFFAOYSA-N n-[2-(3,5-dibromophenyl)propan-2-yl]-2-[4-(4-fluorophenyl)piperidin-4-yl]-n-methylacetamide Chemical compound C=1C(Br)=CC(Br)=CC=1C(C)(C)N(C)C(=O)CC1(C=2C=CC(F)=CC=2)CCNCC1 ZNYREVKCPQKHSI-UHFFFAOYSA-N 0.000 description 1
MFDSKCSKNADMNN-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C(=CC(F)=CC=1)C)CC(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MFDSKCSKNADMNN-UHFFFAOYSA-N 0.000 description 1
VLOOJIHMDCCLTG-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluorophenyl)-1-methylpiperidin-4-yl]-n-methylacetamide Chemical compound C1CN(C)CCC1(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VLOOJIHMDCCLTG-UHFFFAOYSA-N 0.000 description 1
AAEDYOFWXQGHFD-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-3-(4-fluoropiperidin-4-yl)-n-methylpropanamide Chemical compound C=1C=C(F)C=CC=1C(C1(F)CCNCC1)CC(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AAEDYOFWXQGHFD-UHFFFAOYSA-N 0.000 description 1
AENVRNKSHWWCJR-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-n-methyl-3-piperidin-4-ylpropanamide Chemical compound C1CNCCC1C(C=1C=CC(F)=CC=1)CC(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AENVRNKSHWWCJR-UHFFFAOYSA-N 0.000 description 1
229960000515 nafcillin Drugs 0.000 description 1
GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
229960000808 netilmicin Drugs 0.000 description 1
ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 description 1
229960005163 netupitant Drugs 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
208000002042 onchocerciasis Diseases 0.000 description 1
229940023490 ophthalmic product Drugs 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
229950006784 orvepitant Drugs 0.000 description 1
229960000625 oxytetracycline Drugs 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229960000292 pectin Drugs 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000000649 photocoagulation Effects 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
230000002165 photosensitisation Effects 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
229960002292 piperacillin Drugs 0.000 description 1
WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229940044476 poloxamer 407 Drugs 0.000 description 1
229920001992 poloxamer 407 Polymers 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920000233 poly(alkylene oxides) Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000010318 polygalacturonic acid Substances 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
150000007519 polyprotic acids Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
238000012797 qualification Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
FIVSJYGQAIEMOC-ZGNKEGEESA-N rolapitant Chemical compound C([C@@](NC1)(CO[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2C=CC=CC=2)C[C@@]21CCC(=O)N2 FIVSJYGQAIEMOC-ZGNKEGEESA-N 0.000 description 1
229960001068 rolapitant Drugs 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
229960005224 roxithromycin Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000002412 selectin antagonist Substances 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
239000004055 small Interfering RNA Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000003440 styrenes Chemical class 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
229960002673 sulfacetamide Drugs 0.000 description 1
VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960001608 teicoplanin Drugs 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229960004659 ticarcillin Drugs 0.000 description 1
OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
230000008733 trauma Effects 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
229960005041 troleandomycin Drugs 0.000 description 1
LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
229960000497 trovafloxacin Drugs 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
239000002525 vasculotropin inhibitor Substances 0.000 description 1
229950000578 vatalanib Drugs 0.000 description 1
YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
229950007305 vestipitant Drugs 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
229950005485 vofopitant Drugs 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1